📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Affimed

1.1 - Company Overview

Affimed Logo

Affimed

Headquarter: Germany
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of innate cell engager (ICE) antibody therapeutics for cancer, including AFM13 (CD30/CD16A), AFM24 (EGFR-directed engaging NK cells and macrophages), and AFM28 (CD123/CD16A for AML), plus the ROCK platform for customizable ICEs, ongoing clinical trials, and partnerships with pharmaceutical companies.

Products and services

  • AFM24: EGFR-directed innate cell engager that recruits NK cells and macrophages to elicit anti-tumor responses against EGFR-expressing tumors, showing promise in treating such tumors
  • Acimtamig (AFM13): First-in-class innate cell engager targeting CD30 on cancer cells and CD16A on innate immune cells, demonstrating antitumor activity in clinical trials
  • AFM28: CD123-directed innate cell engager targeting leukemic cells and CD16A on NK cells, developed for patients with acute myeloid leukemia to facilitate NK-mediated tumor cell killing

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Affimed

Vyriad Logo

Vyriad

HQ: United States Website
  • Description: Provider of clinical-stage oncolytic virotherapies and gene therapy platforms, including Voyager-V1 (VSV-based oncolytic virotherapy in trials for multiple cancers), Measles-NIS (oncolytic measles virus encoding NIS for precision targeting and monitoring), oncolytic virus platforms using VSV and measles, in vivo gene therapy vectors, and engineered lentiviral vectors; conducts phase 1/2 clinical trials.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vyriad company profile →
Y-mAbs Therapeutics Logo

Y-mAbs Therapeutics

HQ: United States Website
  • Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
Alentis Therapeutics Logo

Alentis Therapeutics

HQ: Switzerland Website
  • Description: Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Alentis Therapeutics company profile →
Active Biotech Logo

Active Biotech

HQ: Sweden Website
  • Description: Provider of biotechnology research and development of pharmaceuticals and vaccines, based on knowledge of autoimmune/inflammatory diseases and cancer, developing products to treat conditions including multiple sclerosis and lung and renal diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Active Biotech company profile →
Arresto Biosciences Logo

Arresto Biosciences

HQ: United States Website
  • Description: Provider of medicine development targeting extracellular matrix molecules to treat cancer and fibrotic diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Arresto Biosciences company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Affimed

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Affimed

2.2 - Growth funds investing in similar companies to Affimed

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Affimed

4.2 - Public trading comparable groups for Affimed

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Affimed

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Affimed

What does Affimed do?

Affimed is a provider of innate cell engager (ICE) antibody therapeutics for cancer, including AFM13 (CD30/CD16A), AFM24 (EGFR-directed engaging NK cells and macrophages), and AFM28 (CD123/CD16A for AML), plus the ROCK platform for customizable ICEs, ongoing clinical trials, and partnerships with pharmaceutical companies.

Who are Affimed's competitors?

Affimed's competitors and similar companies include Vyriad, Y-mAbs Therapeutics, Alentis Therapeutics, Active Biotech, and Arresto Biosciences.

Where is Affimed headquartered?

Affimed is headquartered in Germany.

How many employees does Affimed have?

Affimed has 1,000 employees 🔒.

When was Affimed founded?

Affimed was founded in 2010 🔒.

What sector and industry vertical is Affimed in?

Affimed is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Affimed

Who are the top strategic acquirers in Affimed's sector and industry

Top strategic M&A buyers and acquirers in Affimed's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Affimed?

Top strategic M&A buyers groups and sectors for Affimed include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Affimed's sector and industry vertical

Which are the top PE firms investing in Affimed's sector and industry vertical?

Top PE firms investing in Affimed's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Affimed's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Affimed's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Affimed's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Affimed include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Affimed's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Affimed?

The key public trading comparables and valuation benchmarks for Affimed include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Affimed for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Affimed with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Affimed's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Affimed with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Affimed's' sector and industry vertical?

Access recent funding rounds and capital raises in Affimed's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Affimed